Fate Therapeutics, Inc. (FATE) — Financial statements
Income statement, balance sheet, and cash flow for Fate Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 7↓51.2% | 14↓78.5% | 64↓34.0% | 96↑72.4% | 56 | |
| Cost of Revenue | 13 | 0.00↓100.0% | 157↑1042.5% | 14↑135.2% | 6 | |
| Gross Profit | -6↓145.9% | 14↑114.6% | -94↓213.5% | 83↑65.1% | 50 | |
| Operating Expenses | ||||||
| R&D Expenses | 108↓20.1% | 135↓21.8% | 173↓46.1% | 320↑48.7% | 216 | |
| General & Administrative Expenses | 47↓37.3% | 74↓8.9% | 81↓3.3% | 84↑46.9% | 57 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 15 | 0.00 | 0.00 | |
| SG&A Expenses | 47↓37.3% | 74↓23.4% | 97↑15.0% | 84↑46.9% | 57 | |
| Other Expenses | -13↓187.5% | 15↑108.5% | -173↓1154.5% | -14↓135.2% | -6 | |
| Operating Expenses | 141↓36.8% | 224↑131.2% | 97↓75.2% | 391↑46.4% | 267 | |
| Total Costs & Expenses | 154↓31.1% | 224↓11.9% | 254↓37.2% | 405↑48.3% | 273 | |
| Operating Results | ||||||
| Operating Income | -148↑29.8% | -210↓10.4% | -191↑38.2% | -308↓42.1% | -217 | |
| Depreciation & Amortization | 9↓51.0% | 19↑3.7% | 18↑32.9% | 14↑135.2% | 6 | |
| EBITDA | -127↑28.1% | -177↓2.5% | -172↑41.5% | -295↓39.5% | -211 | |
| EBIT | -136↑30.3% | -196↓2.6% | -191↑38.2% | -308↓42.1% | -217 | |
| Interest & Other Income | ||||||
| Net Interest Income | 11↓36.1% | 17↑0.6% | 17↑194.2% | 6↑346.3% | 1 | |
| Interest Income | 11↓36.1% | 17↑0.6% | 17↑194.2% | 6↑346.3% | 1 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -11↑22.7% | -15 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 11↓52.6% | 24↓18.8% | 30↑10.9% | 27↑450.6% | 5 | |
| Income Before Tax | -136↑26.8% | -186↓15.7% | -161↑42.9% | -282↓32.8% | -212 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -136↑26.8% | -186↓15.7% | -161↑42.9% | -282↓32.8% | -212 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -136↑26.8% | -186↓15.7% | -161↑42.9% | -282↓32.8% | -212 | |
| Bottom-Line Net Income | -136↑26.8% | -186↓15.7% | -161↑42.9% | -282↓32.8% | -212 | |
| EPS (Basic) | -1.15↑29.9% | -1.64↑0.0% | -1.64↑43.6% | -2.91↓29.9% | -2.24 | |
| EPS (Diluted) | -1.15↑29.9% | -1.64↑0.0% | -1.64↑43.6% | -2.91↓29.9% | -2.24 | |
| Weighted Average Shares | 119↑4.5% | 114↑15.5% | 98↑1.6% | 97↑2.2% | 95 | |
| Weighted Average Diluted Shares | 119↑4.5% | 114↑15.5% | 98↑1.6% | 97↑2.2% | 95 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.